Results 31 to 40 of about 146,670 (267)

Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer [PDF]

, 2015
Anaplastic thyroid cancer (ATC) is often incurable so new therapeutic approaches are needed. Tyrosine kinases inhibitors (such as imanitib, sunitinib or sorafenib) are under evaluation for the treatment of ATC.
Bond JA, Cohen EE, Dowlati A, Goulart B, Grande E, Hayashi N, Ibrahim N, Klopper JP, Mahlknecht U, Ohta K, Ruggeri RM, Sherman SI   +11 more
core   +1 more source

Papillary Thyroid Carcinoma with Primary Hyperparathyroidism: A Report of Two Cases and a Brief Literature Review

Endocrinology Research and Practice, 2013
Coexistence of medullary thyroid carcinoma and primary hyperparathyroidism (PHPT) is well described, however, the association of non-medullary thyroid cancer and PHPT is less recognized.
Mehmet Aşık, Inan Anaforoğlu, Mustafa Köse, Savaş Karyagar, Beyhan Mollamehmetoğlu, Ekrem Algün   +5 more
doaj   +1 more source

Update on Targeted Therapy in Medullary Thyroid Cancer

Frontiers in Endocrinology, 2021
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor that accounts for 2-4% of all thyroid cancers. All inherited MTC and approximately 50% of sporadic cases are driven by mutations in the RE arranged during T ransfection (RET) proto-oncogene.
Christian Okafor, J. Hogan, M. Raygada, B. J. Thomas, S. Akshintala, J. Glod, Jaydira Del Rivero   +6 more
semanticscholar   +1 more source

Pediatric thyroid disease: when is surgery necessary, and who should be operating on our children? [PDF]

, 2013
Surgical diseases of the thyroid in the pediatric population represent a diverse set of both benign and malignant conditions. Overall, incidence is rare.
Breuer, Christopher, Solomon, Daniel, Sosa, Julie Ann, Tuggle, Charles   +3 more
core   +1 more source

Comprehensive Immune Profiling of Medullary Thyroid Cancer

Thyroid, 2020
Background: Despite advances in targeted kinase inhibitor development for patients with medullary thyroid cancer (MTC), most patients develop resistance and would benefit from alternative approaches. Immune-based therapies are now considered for patients
N. Pozdeyev, T. A. Erickson, Lian Zhang, K. Ellison, C. Rivard, S. Sams, F. Hirsch, B. Haugen, J. French   +8 more
semanticscholar   +1 more source

Educational Case: Endocrine Neoplasm

Academic Pathology, 2018
Medullary thyroid cancer is a rare neuroendocrine tumor that arises the neural crest-derived parafollicular C cells and accounts for approximately 5% to 10% of thyroid cancers worldwide.
Sheila Segura MD, Gloria Ramos-Rivera MD, Mark Suhrland MD   +2 more
doaj   +1 more source

Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys

Frontiers in Endocrinology, 2022
Thyroid cancer is the malignant tumor that is increasing most rapidly in the world, mainly at the expense of sporadic papillary thyroid carcinoma. The somatic alterations involved in the pathogenesis of sporadic follicular cell derived tumors are well ...
María Sánchez-Ares, Soledad Cameselle-García, Ihab Abdulkader-Nallib, Ihab Abdulkader-Nallib, Gemma Rodríguez-Carnero, Carolina Beiras-Sarasquete, José Antonio Puñal-Rodríguez, José Antonio Puñal-Rodríguez, José Manuel Cameselle-Teijeiro, José Manuel Cameselle-Teijeiro   +9 more
doaj   +1 more source

Medullary Thyroid Cancer: An Introduction [PDF]

Current Oncology, 2019
Medullary thyroid cancer (mtc) is a rare cancer, making up perhaps only a few percent of all thyroid cancers […]
openaire   +2 more sources

Mutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation. [PDF]

, 2016
BackgroundWell-differentiated thyroid cancer (WDTC) incidence in pediatrics is rising, most being papillary thyroid carcinoma (PTC). The objective of the study was to assess the prevalence of different mutations in pediatric WDTC and correlate the ...
Cheng, Shih-Min, Hantash, Feras M, Jiang, Wen, McPhaul, Michael J, Newbury, Robert O, Newfield, Ron S, Nikita, Maria Eleni, Phillips, Susan A, Reitz, Richard E, Waldman, Frederic M   +9 more
core   +1 more source

A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC [PDF]

, 2015
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor mediating the toxicity and tumor-promoting properties of dioxin. AHR has been reported to be overexpressed and constitutively active in a variety of solid tumors, but few data
Barollo, Susi, Bertazza, Loris, Bisognin, Andrea, Bortoluzzi, Stefania, Boscaro, Marco, Ceccato, Filippo, Ciato, Denis, Galuppini, Francesca, Guzzardo, Vincenza, Jaffrain Rea, Marie Lise, Mian, Caterina, Occhi, Gianluca, Pennelli, Gianmaria, Regazzo, Daniela, Scaroni, Carla, Vianello, Federica, WATUTANTRIGE FERNANDO, Sara   +16 more
core   +4 more sources